3-(1H-咪唑-1-基)苯甲胺 | 1311315-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(1H-咪唑-1-基)苯甲胺
• 英文名称: (3-(1H-Imidazol-1-YL)phenyl)methanamine
• 英文别名: (3-imidazol-1-ylphenyl)methanamine
• CAS: 1311315-11-3
• 化学式: C₁₀H₁₁N₃
• mdl: MFCD18917359
• 分子量: 173.21
• InChiKey: XTMGJUHDNSODLY-UHFFFAOYSA-N

物化性质

• 沸点：
  359.8±25.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-(1-tert-butyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl)thiazol-4-yl)acetic acid 、 3-(1H-咪唑-1-基)苯甲胺 生成 2-{2-[1-tert-butyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]-1,3-thiazol-4-yl}-N-[3-(1H-imidazol-1-yl)benzyl]acetamide
  参考文献：
  名称：

  Heterocyclic compound

  摘要：

  提供一种具有RORγt抑制活性的杂环化合物，该化合物为式（I）或其盐。该化合物具有环A，该环为可选取代的环基团，并通过Q与吡唑环结合。Q为键，可选取代的C1-10烷基，可选取代的C2-10烯基或可选取代的C2-10炔基。R1为取代基。环B为噻唑环、异噻唑环或二氢噻唑环，除R2外还可选取代一个取代基。R2为可选取代的环基-羰基-C1-6烷基、可选取代的氨基羰基-C1-6烷基、可选取代的环基-C1-6烷基、可选取代的环基-C1-6烷基氨基羰基基团、可选取代的氨基羰基-C2-6烯基基团、可选取代的C1-6烷基羰基氨基-C1-6烷基基团、可选取代的环基-氨基羰基基团、可选取代的环基-羰基基团或可选取代的非芳香杂环基团。

  公开号：

  US09156837B2

文献信息

• Adenine derivatives as protein kinase inhibitors
  申请人：B.C.I. PHARMA

  公开号：US11236093B2

  公开（公告）日：2022-02-01

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3′, R4, R4′, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

  本发明涉及根据通式(Ⅰ)[化合物(C)，以下同]的适于用作激酶抑制剂的化合物，或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体，式(Ⅰ)其中A、R1、R2、R3、R3′、R4、R4′、X、Y、Z、T如权利要求书中所定义。本发明进一步涉及一种抑制蛋白激酶活性的体外方法，该方法包括使蛋白激酶与式(I)化合物或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体接触。本发明进一步涉及式（I）化合物本身及其作为药物的用途，以及用于治疗由蛋白激酶介导的选自癌症、炎症性疾病、心血管疾病、病毒引起的疾病、循环系统疾病、纤维增生性疾病和痛觉过敏性疾病的方法。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2738170B1

  公开（公告）日：2017-08-30
• ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：B.C.I. PHARMA

  公开号：US20190127379A1

  公开（公告）日：2019-05-02

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R 1 , R 2 , R 3 , R 3′ , R 4 , R 4′ , X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.
• US9156837B2
  申请人：——

  公开号：US9156837B2

  公开（公告）日：2015-10-13